vs
ESCALADE INC（ESCA）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
ESCALADE INC的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.8倍（$62.6M vs $35.5M），ESCALADE INC净利率更高（5.9% vs -304.2%，领先310.2%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -2.2%），ESCALADE INC自由现金流更多（$13.7M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 4.5%）
Escalade Inc是一家专业体育用品制造及分销商，主营篮球架、射箭装备、乒乓球器材、游戏桌及户外休闲配件，核心市场覆盖北美、欧洲及亚太地区，服务客户涵盖零售消费、商业健身、专业体育分销等领域。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
ESCA vs RXRX — 直观对比
营收规模更大
ESCA
是对方的1.8倍
$35.5M
营收增速更快
RXRX
高出683.9%
-2.2%
净利率更高
ESCA
高出310.2%
-304.2%
自由现金流更多
ESCA
多$61.0M
$-47.3M
两年增速更快
RXRX
近两年复合增速
4.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $62.6M | $35.5M |
| 净利润 | $3.7M | $-108.1M |
| 毛利率 | 27.7% | 59.8% |
| 营业利润率 | 8.2% | -304.8% |
| 净利率 | 5.9% | -304.2% |
| 营收同比 | -2.2% | 681.7% |
| 净利润同比 | 37.1% | 39.6% |
| 每股收益（稀释后） | $0.27 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESCARXRX
| Q4 25 | $62.6M | $35.5M | ||
| Q3 25 | $67.8M | $5.2M | ||
| Q2 25 | $54.3M | $19.2M | ||
| Q1 25 | $55.5M | $14.7M | ||
| Q4 24 | $63.9M | $4.5M | ||
| Q3 24 | $67.7M | $26.1M | ||
| Q2 24 | $62.5M | $14.4M | ||
| Q1 24 | $57.3M | $13.8M |
净利润ESCARXRX
| Q4 25 | $3.7M | $-108.1M | ||
| Q3 25 | $5.6M | $-162.3M | ||
| Q2 25 | $1.8M | $-171.9M | ||
| Q1 25 | $2.6M | $-202.5M | ||
| Q4 24 | $2.7M | $-178.9M | ||
| Q3 24 | $5.7M | $-95.8M | ||
| Q2 24 | $2.8M | $-97.5M | ||
| Q1 24 | $1.8M | $-91.4M |
毛利率ESCARXRX
| Q4 25 | 27.7% | 59.8% | ||
| Q3 25 | 28.1% | -183.8% | ||
| Q2 25 | 24.7% | -4.9% | ||
| Q1 25 | 26.7% | -48.0% | ||
| Q4 24 | 24.9% | -181.4% | ||
| Q3 24 | 24.8% | 53.7% | ||
| Q2 24 | 24.2% | 36.2% | ||
| Q1 24 | 25.0% | 19.1% |
营业利润率ESCARXRX
| Q4 25 | 8.2% | -304.8% | ||
| Q3 25 | 10.8% | -3327.6% | ||
| Q2 25 | 4.8% | -916.8% | ||
| Q1 25 | 6.6% | -1297.9% | ||
| Q4 24 | 7.1% | -4042.4% | ||
| Q3 24 | 11.8% | -377.1% | ||
| Q2 24 | 7.1% | -697.4% | ||
| Q1 24 | 5.3% | -698.4% |
净利率ESCARXRX
| Q4 25 | 5.9% | -304.2% | ||
| Q3 25 | 8.2% | -3135.3% | ||
| Q2 25 | 3.4% | -894.2% | ||
| Q1 25 | 4.7% | -1373.3% | ||
| Q4 24 | 4.2% | -3935.5% | ||
| Q3 24 | 8.4% | -367.5% | ||
| Q2 24 | 4.5% | -676.6% | ||
| Q1 24 | 3.1% | -662.4% |
每股收益（稀释后）ESCARXRX
| Q4 25 | $0.27 | $-0.17 | ||
| Q3 25 | $0.40 | $-0.36 | ||
| Q2 25 | $0.13 | $-0.41 | ||
| Q1 25 | $0.19 | $-0.50 | ||
| Q4 24 | $0.20 | $-0.56 | ||
| Q3 24 | $0.40 | $-0.34 | ||
| Q2 24 | $0.20 | $-0.40 | ||
| Q1 24 | $0.13 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $743.3M |
| 总债务越低越好 | $18.5M | $9.6M |
| 股东权益账面价值 | $173.2M | $1.1B |
| 总资产 | $222.1M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.11× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资ESCARXRX
| Q4 25 | — | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M | ||
| Q1 24 | — | $296.3M |
总债务ESCARXRX
| Q4 25 | $18.5M | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | $25.6M | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益ESCARXRX
| Q4 25 | $173.2M | $1.1B | ||
| Q3 25 | $172.3M | $1.0B | ||
| Q2 25 | $168.3M | $919.1M | ||
| Q1 25 | $168.8M | $933.9M | ||
| Q4 24 | $169.0M | $1.0B | ||
| Q3 24 | $170.1M | $524.6M | ||
| Q2 24 | $166.0M | $584.4M | ||
| Q1 24 | $164.7M | $401.2M |
总资产ESCARXRX
| Q4 25 | $222.1M | $1.5B | ||
| Q3 25 | $232.5M | $1.4B | ||
| Q2 25 | $218.3M | $1.3B | ||
| Q1 25 | $222.1M | $1.3B | ||
| Q4 24 | $226.3M | $1.4B | ||
| Q3 24 | $244.9M | $726.5M | ||
| Q2 24 | $243.1M | $775.9M | ||
| Q1 24 | $256.3M | $557.8M |
负债/权益比ESCARXRX
| Q4 25 | 0.11× | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | 0.15× | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.9M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $13.7M | $-47.3M |
| 自由现金流率自由现金流/营收 | 21.8% | -133.1% |
| 资本支出强度资本支出/营收 | 2.0% | 3.5% |
| 现金转化率经营现金流/净利润 | 4.02× | — |
| 过去12个月自由现金流最近4个季度 | $28.5M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流ESCARXRX
| Q4 25 | $14.9M | $-46.1M | ||
| Q3 25 | $-965.0K | $-117.4M | ||
| Q2 25 | $13.3M | $-76.4M | ||
| Q1 25 | $3.8M | $-132.0M | ||
| Q4 24 | $12.3M | $-115.4M | ||
| Q3 24 | $10.5M | $-59.2M | ||
| Q2 24 | $13.3M | $-82.2M | ||
| Q1 24 | $7.0K | $-102.3M |
自由现金流ESCARXRX
| Q4 25 | $13.7M | $-47.3M | ||
| Q3 25 | $-1.3M | $-117.6M | ||
| Q2 25 | $12.9M | $-79.6M | ||
| Q1 25 | $3.2M | $-133.8M | ||
| Q4 24 | $11.7M | $-116.7M | ||
| Q3 24 | $10.2M | $-63.8M | ||
| Q2 24 | $12.5M | $-83.4M | ||
| Q1 24 | $-350.0K | $-109.0M |
自由现金流率ESCARXRX
| Q4 25 | 21.8% | -133.1% | ||
| Q3 25 | -1.9% | -2272.5% | ||
| Q2 25 | 23.7% | -413.9% | ||
| Q1 25 | 5.9% | -907.4% | ||
| Q4 24 | 18.4% | -2567.7% | ||
| Q3 24 | 15.0% | -244.6% | ||
| Q2 24 | 20.0% | -578.5% | ||
| Q1 24 | -0.6% | -789.9% |
资本支出强度ESCARXRX
| Q4 25 | 2.0% | 3.5% | ||
| Q3 25 | 0.4% | 4.7% | ||
| Q2 25 | 0.8% | 16.4% | ||
| Q1 25 | 1.0% | 12.4% | ||
| Q4 24 | 0.9% | 28.6% | ||
| Q3 24 | 0.5% | 17.5% | ||
| Q2 24 | 1.3% | 8.2% | ||
| Q1 24 | 0.6% | 48.2% |
现金转化率ESCARXRX
| Q4 25 | 4.02× | — | ||
| Q3 25 | -0.17× | — | ||
| Q2 25 | 7.28× | — | ||
| Q1 25 | 1.45× | — | ||
| Q4 24 | 4.55× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 4.67× | — | ||
| Q1 24 | 0.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
